Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide-Pulsed PBMC Vaccine and rhIL-12 +/- IL-2 in Metastatic Melanoma
NCT00203879Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Feb 2002
- Primary completion
- May 2006
- Modality
- Peptides, Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MAGE-3 peptide + Melan-A peptide + gp100 peptide + NA17 peptide + autologous peripheral blood mononuclear cells in melanoma (2 arms), sponsored by University of Chicago. Primary endpoints: Induction of augmented specific IFN-y-producing CD8+ T cells and Clinical Response Rate. Started Feb 2002; status: completed.
02
Drugs
MAGE-3 peptide + Melan-A peptide + gp100 peptide + NA17 peptide + autologous peripheral blood mononuclear cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00203879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203879.